Navigation Links
CV Therapeutics Statement on Unsolicited Proposal From Astellas
Date:1/27/2009

in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina, and Lexiscan(R) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Ranexa(R) (ranolazine prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 DuPont Pioneer announced today that ... president of Agricultural Biotechnology (ABT), effective July 21, 2014. ... most recently as president, chief executive officer and board ... in the seed and crop protection industry to this ... Schickler , president of DuPont Pioneer. “I am looking ...
(Date:7/23/2014)... BRUSSELS , July 23, 2014 regulated ... its research and development pipeline with positive topline ... brivaracetam . This study was designed to evaluate ... (100 and 200 mg/day, without titration) compared to ... patients with partial-onset seizures, not fully controlled despite ...
(Date:7/23/2014)... 23, 2014  GrowBLOX Sciences, Inc. (OTCQB: GBLX), a medical ... filing for two medical marijuana dispensary locations in ... to the Clark County, Nevada dispensary ... as previously announced.  GrowBLOX Sciences, CEO Craig ... new applications for dispensaries in the City of ...
(Date:7/23/2014)... China Cord Blood Corporation (NYSE: CO ) ("CCBC" or ... blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell ... catering to the mother and child segment, today announced that the ... Singapore , Hong Kong , ... the Philippines and Malaysia ...
Breaking Biology Technology:DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4
... Partners announced,today that it has initiated coverage on ... promising drug development pipeline for treating a,variety of ... on two,drug development programs; the first is MN-221 ... estimated 2,000,000 visits to the emergency room,a year ...
... Third Party Administrators,Alliance (TPAA) announced today the appointment ... the nation,s first alliance of third party,administrators and ... to its members., Oelschlager brings hands-on experience ... role, assets he believes will further the,organization,s reach ...
... PRXL ), a leading global biopharmaceutical services,organization, ... Goldberg, M.D.,to Chief Operating Officer (COO). Dr. Goldberg ... Perceptive Informatics at,PAREXEL. He will continue to oversee ... von Rickenbach, Chairman and Chief Executive Officer of ...
Cached Biology Technology:Vista Partners Initiates Coverage on MediciNova Inc. (Nasdaq: MNOV) 2The TPAA Names Mark Oelschlager President 2PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 2PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 3PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 4
(Date:7/24/2014)... into the potato genes that best adapt to the ... rainfall and increased extremes of hot and cold temperatures.The ... order to create new potato varieties that will adapt ... to find out how the current potato varieties will ... and lower temperatures. , This research is part of ...
(Date:7/24/2014)... primordial soup in which life arose have been maintained in ... East Anglia. , Research published today in the Journal ... and very likely also in animals still perform ancient reactions ... some four billion years ago. , The primordial soup ... as a result of the combination of metals, gases from ...
(Date:7/24/2014)... led by the University of York has carried out ... Western Indian Ocean. , The results, reported in ... revolution in the management of marine protected areas, with ... km in the region now under local community ... the seas and coasts designed to protect wildlife from ...
Breaking Biology News(10 mins):Neiker-Tecnalia is researching the potato genes that best adapt to climate change 2Western Indian Ocean communities play vital role in conservation 2
... revealed a previously unknown mechanism in the body which ... responses and control of blood pressure, pain and appetite. ... help fight health problems connected with these functions in ... and University College London found that lactate essentially ...
... New York, NYFebruary 10, 2014In a study published ... team led by Ken Shepard, professor of electrical ... Lars Dietrich, assistant professor of biological sciences at ... the basis of modern computers and communications devices, ...
... change unfolds over the next century, plants and animals will ... climate. A new study provides an innovative global map of ... up with a changing climate. The findings appear in the ... a UC Santa Barbara National Center for Ecological Analysis and ...
Cached Biology News:New research sheds light on how the body regulates fundamental neuro-hormone 2Chips that listen to bacteria 2Maps show expected redistribution of global species due to climate change 2Maps show expected redistribution of global species due to climate change 3
... MasterAmp™ Taq DNA Polymerase is a ... aquaticus. Having optimal activity at temperatures ... thermostable enzyme used for PCR and ... purpose. The enzyme has an intrinsic ...
... 4100 high pressure dual piston pump and the ... and utra low drift. The WaveQuest ... detection and provides superior stability. Hence ... and for monitoring to the highest of sensitivities. ...
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
Biology Products: